The serine-threonine protein kinase encoded by the AKT1 (AKT serine/threonine kinase 1) gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in AKT1 have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for AKT1.

The Abbkine AKT Mouse Mouse Monoclonal Antibody (10D6) was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen anddetects endogenous levels of AKT1. The antibody has been validaed in WB, IHC-P and reacts with Human samples.

Abbkine supplies below price/size: $100/30μl, $220/100μl, $360/200μl of Mouse Anti-AKT Mouse Monoclonal Antibody (10D6) at https://www.abbkine.com/product/akt-mouse-monoclonal-antibody-10d6-abm40272.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.